JP2025504379A - 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用 - Google Patents

重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用 Download PDF

Info

Publication number
JP2025504379A
JP2025504379A JP2024540912A JP2024540912A JP2025504379A JP 2025504379 A JP2025504379 A JP 2025504379A JP 2024540912 A JP2024540912 A JP 2024540912A JP 2024540912 A JP2024540912 A JP 2024540912A JP 2025504379 A JP2025504379 A JP 2025504379A
Authority
JP
Japan
Prior art keywords
certain embodiments
compound
deuterium
nsd2
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504379A5 (enExample
Inventor
ジョセフ コノリー，テレンス
アーサー ルイス，チャド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
K36 Therapeutics Inc
Original Assignee
K36 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by K36 Therapeutics Inc filed Critical K36 Therapeutics Inc
Publication of JP2025504379A publication Critical patent/JP2025504379A/ja
Publication of JP2025504379A5 publication Critical patent/JP2025504379A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024540912A 2022-01-05 2023-01-05 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用 Pending JP2025504379A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263296676P 2022-01-05 2022-01-05
US63/296,676 2022-01-05
PCT/US2023/010204 WO2023133201A1 (en) 2022-01-05 2023-01-05 Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions

Publications (2)

Publication Number Publication Date
JP2025504379A true JP2025504379A (ja) 2025-02-12
JP2025504379A5 JP2025504379A5 (enExample) 2026-01-14

Family

ID=87074217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540912A Pending JP2025504379A (ja) 2022-01-05 2023-01-05 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用

Country Status (10)

Country Link
US (2) US12492203B2 (enExample)
EP (1) EP4460502A4 (enExample)
JP (1) JP2025504379A (enExample)
KR (1) KR20240158230A (enExample)
CN (1) CN119032094A (enExample)
AU (1) AU2023205553A1 (enExample)
CA (1) CA3242612A1 (enExample)
IL (1) IL314062A (enExample)
MX (1) MX2024008450A (enExample)
WO (1) WO2023133201A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026803A1 (en) 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
CN120641105A (zh) * 2022-12-12 2025-09-12 K36治疗股份有限公司 含有哌啶基甲基嘌呤胺的药物组合物及其在治疗疾病和疾患中的用途
AU2024381513A1 (en) * 2023-11-17 2026-06-04 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN117843641B (zh) * 2023-12-28 2025-04-25 和径医药科技（上海）有限公司 Nsd3抑制剂及其制备方法和应用
WO2025259850A1 (en) * 2024-06-12 2025-12-18 K36 Therapeutics, Inc. Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2021026803A1 (en) 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
CN114981270B (zh) 2019-09-20 2024-10-18 诺华公司 Mll1抑制剂和抗癌剂
AR122159A1 (es) 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
US20250326752A1 (en) 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
JP2025517349A (ja) 2022-05-18 2025-06-05 ケイ３６・セラピューティクス・インコーポレイテッド ピペリジニル－メチル－プリンアミンｄ－酒石酸塩、結晶形態、ならびに医学的疾患及び状態の治療におけるそれらの使用
WO2023225144A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023230038A1 (en) 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
US20250361235A1 (en) 2022-05-23 2025-11-27 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
WO2024055048A1 (en) 2022-09-09 2024-03-14 The Trustees Of Columbia University In The City Of New York Methods of treating neuroendocrine prostate cancer (nepc) by inhibiting nuclear receptor binding set domain protein 2 (nsd2)
CN120641105A (zh) 2022-12-12 2025-09-12 K36治疗股份有限公司 含有哌啶基甲基嘌呤胺的药物组合物及其在治疗疾病和疾患中的用途
AU2024381513A1 (en) 2023-11-17 2026-06-04 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions

Also Published As

Publication number Publication date
CA3242612A1 (en) 2023-07-13
EP4460502A1 (en) 2024-11-13
US20260049083A1 (en) 2026-02-19
MX2024008450A (es) 2024-12-06
CN119032094A (zh) 2024-11-26
US20240352017A1 (en) 2024-10-24
AU2023205553A1 (en) 2024-07-25
WO2023133201A1 (en) 2023-07-13
US12492203B2 (en) 2025-12-09
KR20240158230A (ko) 2024-11-04
IL314062A (en) 2024-09-01
EP4460502A4 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
US12492203B2 (en) Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions
US20250326752A1 (en) Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
EP3423443B1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
US20240002385A1 (en) Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225144A1 (en) Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20250171445A1 (en) Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
EP4633637A1 (en) Pharmaceutical compositions containing a piperidinyl-methyl-purine amine and their use in treating diseases and conditions
WO2023230026A1 (en) Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
US12371434B2 (en) MLL1 inhibitors and anti-cancer agents
WO2023230038A1 (en) Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
KR20220050963A (ko) Mll1 억제제 및 항암제
US20240415864A1 (en) Carbohydrate-functionalized piperidinyl-methylpurine pyridines and related compounds and their use in treating diseases and conditions
WO2025259850A1 (en) Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions
US20240417401A1 (en) Heterobicyclic-methylpurine pyridines and related compounds and their use in treating diseases and conditions
US20250163067A1 (en) Nucleobase-substituted piperidinyl-pyridines and related compounds and their use in treating diseases and conditions
WO2024258897A1 (en) Alkoxypyridinyl and related compounds and their use in therapy
WO2025117672A1 (en) Indazolyl-piperidine sulfonamides and related compounds and their use in therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251225